Cat. #160974
ROVA023 Ovarian cancer organoid
Cat. #: 160974
Sub-type: Organoids
Unit size: 40-100 uL of cell pellet/vial, 1ml
Availability: 8-10 weeks
Organism: Human
Tissue: Ovarian
£2,500.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Medical-Industrial Translational Research Center
Institute: Fukushima Medical University
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Tool name: ROVA023 Ovarian cancer organoid
- Alternate name: ROVA023, ROVA23
- Cancer: Gynaecologic cancer
- Cancers detailed: Ovarian;Serous carcinoma
- Age y o : 68
- Research fields: Cancer
- Tool sub type: Organoids
- Organism: Human
- Tissue: Ovarian
- Gender: Female
- Growth properties: Suspension
- Application: 3D cell culture, High-throughput screening
- Description: A series of novel patient-derived organoids (PDOs) have been constructed from different tumor tissue types under the Fukushima Translational Research Project, designated as F-PDO. F-PDOs form large cell clusters with a morphology similar to the original tumor and can be cultured for more than six months. Our comparative histological and comprehensive gene expression analyses have shown that the characteristics of F-PDOs were similar to their source tumors, even after long-term growth in culture conditions
- Biosafety level: 2
Handling
- Format: Frozen
- Passage number: 5
- Growth medium: Cancer Cell Expansion Media plus (Fujifilm Wako Pure Chemical, Ltd.) with 10 ng/mL bFGF, 10 ÄM Y-27632, 30 ng/mL EGF, and 1 ÄM A-83-01.
- Temperature: 37° C
- Atmosphere: 5% CO2
- Volume: 1 ml
- Storage medium: CELLBANKER 2
- Storage conditions: Liquid Nitrogen
- Shipping conditions: Dry ice
- Characterisation tests: Pathogen and stelility test; Comprehensive gene expression analysis; Cancer panel sequencing; Whole exome sequencing; Anticancer drug susceptibility testing
- Mycoplasma free: Yes
- Biosafety level: 2
Application Details
- Application: 3D cell culture, High-throughput screening
